N. R. Landau

This study demonstrates that AAV vectors expressing ACE2 decoy receptors can protect mice against SARS-CoV-2 infection, including recent Omicron subvariants, even when administered post-infection.

This study demonstrates that an ACE2 receptor decoy protein effectively reduces SARS-CoV-2 virus loads in mice against both parental and Omicron variants.

This study evaluates the neutralization of SARS-CoV-2 Omicron BA.2 by therapeutic monoclonal antibodies, finding reduced neutralization by several antibodies but retention of activity by the AZD8895+AZD1061 cocktail.

This study evaluates neutralization of SARS-CoV-2 Mu and C.1.2 variants by vaccine-elicited and convalescent antibodies, finding that vaccine-induced responses remain protective despite partial resistance.

The paper assesses Omicron's resistance to vaccine and monoclonal antibody neutralization, finding boosters improve efficacy but existing therapies are largely ineffective.

This study compares neutralizing antibody titers from mRNA and adenoviral vector vaccines against SARS-CoV-2 variants, finding lower neutralization against variants for Ad26.COV2.S and suggesting a second dose may improve protection.

This study examines inter-individual variability in SARS-CoV-2 infection of intestinal organoids, finding that ACE2 expression levels determine susceptibility and that Omicron variant shows higher infectivity.

This study assesses the neutralization efficacy of convalescent sera and mRNA vaccine-elicited antibodies against the SARS-CoV-2 lambda variant, finding minimal reduction in neutralizing titers.

This study investigates SARS-CoV-2 infection in placentas from infected pregnant women, finding that the virus infects syncytiotrophoblast cells and triggers maternal immune cell infiltration.

This study evaluates the neutralization resistance of SARS-CoV-2 B.1.617 and B.1.618 spike proteins to vaccine-elicited and therapeutic antibodies, finding partial resistance due to specific mutations.

The paper assesses neutralization of B.1.526 SARS-CoV-2 variants by vaccine-elicited and therapeutic antibodies, finding minimal impact on neutralizing titers.

This study evaluates the neutralization activity of two monoclonal antibodies against SARS-CoV-2 variants, finding reduced efficacy against B.1.351 and mink cluster 5 due to specific spike protein mutations.

This study evaluates the neutralizing activity of convalescent sera and BNT162b2 vaccine antibodies against SARS-CoV-2 variants, showing reduced efficacy against B.1.351 due to E484K mutation but overall maintained protection.

This study investigates antibody targeting of the ACE2-binding interface of SARS-CoV-2 Spike, finding that only a small fraction of RBD-binding antibodies target this region, suggesting it is less immunogenic.

The paper describes a modified soluble ACE2 protein that effectively inhibits SARS-CoV-2 infection in cell culture with higher potency than previous versions.

The paper assesses neutralization capacity and antibody titers against SARS-CoV-2 antigens in recovered healthcare workers, finding that high titers of multiple isotypes correlate with neutralization.